Levosimendan is used intravenously for the management of heart failure. At the therapeutic dose, levosimendan acts predominantly as a calcium sensitizer and ATP-sensitive K^+^-channel (KATP-channel) opener. It binds directly to the calcium-dependent site on troponin C, stabilizing the calcium-induced conformational change and enhances the calcium sensitivity of the cardiac myofilaments. The advantages of a calcium sensitizer over dobutamine is the lack of intracellular calcium overload and that it acts without increasing the energy demand for handling intracellular calcium.

Method
======

Fifteen patients with cardiogenic, septic or mixed cardiogenic/septic shock were administered a loading dose of 12 μg/kg/min levosimendan, followed by a continuous infusion of 0.1 μg/kg/min for 24 hours. Five patients were diagnosed with septic shock, six with cardiogenic shock and four with mixed septic and cardiogenic shock. The mean APACHE II score was 21.3 ± 6.4 The arterial blood pressures of the patients were monitored closely via arterial catheters. Intravenous noradrenaline was administered, where necessary, to maintain mean arterial pressure \> 65 mmHg. Echocardiographic left ventricular ejection fraction (LVEF) (Simpson\'s method) and plasma B-type natriuretic peptide (Biosite Triage method) were measured before and after (within 1 hour) levosimendan infusion.

Results
=======

The LVEF showed a significantly but relatively small improvement in response to levosimendan infusion (pre, 25.7 ± 11.0% vs post, 29.8 ± 8.6%), representing an absolute change of 4.1 ± 8.4% (*P*= 0.039). The plasma B-type natriuretic peptide concentrations demonstrated a significant decrease, from 993 ± 389 to 644 ± 408 pg/ml, before and after levosimendan infusion (*P*= 0.001).

Conclusion
==========

The use of levosimendan in shock patients proved to be feasible, and holds promise as a potential alternative to catecholamine inotropes.
